Volitinib
99%
- Product Code: 102464
CAS:
1313725-88-0
| Molecular Weight: | 345.36 g./mol | Molecular Formula: | C₁₇H₁₅N₉ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD28359096 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Volitinib is primarily used in the field of oncology as a targeted therapy for certain types of cancers. It functions as a kinase inhibitor, specifically targeting and inhibiting the activity of enzymes involved in cancer cell growth and proliferation. This makes it effective in treating cancers that are driven by specific genetic mutations or overactive signaling pathways.
One of its key applications is in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer cells exhibit mutations in the epidermal growth factor receptor (EGFR). By blocking these receptors, Volitinib helps to slow down or halt the progression of the cancer.
Additionally, Volitinib has shown promise in clinical trials for other types of cancers, such as breast cancer and colorectal cancer, especially in patients who have developed resistance to other forms of targeted therapy. Its ability to selectively target cancer cells while sparing normal cells reduces the severity of side effects compared to traditional chemotherapy.
Research is ongoing to explore its potential in combination therapies, where it is used alongside other drugs to enhance its efficacy and overcome resistance mechanisms in cancer cells. This makes Volitinib a valuable tool in the evolving landscape of precision medicine for cancer treatment.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | ฿5,877.00 |
+
-
|
Volitinib
Volitinib is primarily used in the field of oncology as a targeted therapy for certain types of cancers. It functions as a kinase inhibitor, specifically targeting and inhibiting the activity of enzymes involved in cancer cell growth and proliferation. This makes it effective in treating cancers that are driven by specific genetic mutations or overactive signaling pathways.
One of its key applications is in the treatment of non-small cell lung cancer (NSCLC), particularly in cases where the cancer cells exhibit mutations in the epidermal growth factor receptor (EGFR). By blocking these receptors, Volitinib helps to slow down or halt the progression of the cancer.
Additionally, Volitinib has shown promise in clinical trials for other types of cancers, such as breast cancer and colorectal cancer, especially in patients who have developed resistance to other forms of targeted therapy. Its ability to selectively target cancer cells while sparing normal cells reduces the severity of side effects compared to traditional chemotherapy.
Research is ongoing to explore its potential in combination therapies, where it is used alongside other drugs to enhance its efficacy and overcome resistance mechanisms in cancer cells. This makes Volitinib a valuable tool in the evolving landscape of precision medicine for cancer treatment.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :